Compare Novartis AG (NVS) vs Eli Lilly and Company (LLY) Stock

Novartis AG (NVS) offers the better valuation at 23.5x trailing P/E (19.0x forward), making it the more compelling value choice. Analysts rate Eli Lilly and Company (LLY) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novartis AG (NVS) is the cheapest at 23.5x versus Eli Lilly and Company at 89.9x. On forward P/E, Novartis AG is actually cheaper at 19.0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novartis AG wins at 1.24x versus Eli Lilly and Company's 5.02x — a reasonable growth-adjusted valuation.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +421.2%, compared to +119.5% for Novartis AG (NVS). A $10,000 investment in LLY five years ago would be worth approximately $52K today (assuming dividends reinvested). Over 10 years, the gap is even starker: LLY returned +1412% versus NVS's +221.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Novartis AG (NVS) is the lower-risk stock at 0.24β versus Eli Lilly and Company's 0.65β — meaning LLY is approximately 169% more volatile than NVS relative to the S&P 500. On balance sheet safety, Novartis AG (NVS) carries a lower debt/equity ratio of 80% versus 2% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

Novartis AG (NVS) is the more profitable company, earning 25.6% net margin versus 23.5% for Eli Lilly and Company — meaning it keeps 25.6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 38.9% versus 31.2% for NVS. At the gross margin level — before operating expenses — LLY leads at 81.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential. By this metric, Novartis AG (NVS) is the more undervalued stock at a PEG of 1.24x versus Eli Lilly and Company's 5.02x. A PEG below 1.5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Novartis AG (NVS) trades at 19.0x forward P/E versus 30.9x for Eli Lilly and Company — 11.9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 15.4% to $1214.28.

All stocks in this comparison pay dividends. Novartis AG (NVS) offers the highest yield at 2.4%, versus 0.5% for Eli Lilly and Company (LLY).

For long-horizon retirement investors, Novartis AG (NVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.24), 2.4% yield, +221.6% 10Y return). Both have compounded well over 10 years (NVS: +221.6%, LLY: +1412%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. NVS pays a dividend while LLY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.